Back to Search
Start Over
Risks and benefits of systematic lymphadenectomy during interval debulking surgery for advanced high grade serous ovarian cancer.
- Source :
-
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2022 Jan; Vol. 48 (1), pp. 275-282. Date of Electronic Publication: 2021 Nov 03. - Publication Year :
- 2022
-
Abstract
- Background: Lymphadenectomy is debated in patients with ovarian cancer. The aim of our study was to evaluate the impact of lymphadenectomy in patients with high-grade serous ovarian cancer receiving neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS).<br />Methods: A retrospective, unicentric study including all patients undergoing NACT and IDS was carried out from 2005 to 2018. Patients with and without lymphadenectomy were compared in terms of recurrence free survival (RFS), overall survival (OS), and complication rates.<br />Results: We included 203 patients. Of these, 133 had a lymphadenectomy (65.5%) and 77 had involved nodes (57.9%). Patients without a lymphadenectomy were older, had a more extensive disease and less complete CRS. No differences were noted between the lymphadenectomy and no lymphadenectomy group concerning 2-year RFS (47.4% and 48.6%, p = 0.87, respectively) and 5-year OS (63.2% versus 58.6%, p = 0.41, respectively). Post-operative complications tended to be more frequent in the lymphadenectomy group (18.57% versus 31.58%, p = 0.09). In patients with a lymphadenectomy, survival was significantly altered if the nodes were involved (positive nodes: 2-year RFS 42.5% and 5-year OS 49.4%, negative nodes: 2-year RFS 60.7% and 5-year OS 82.2%, p = 0.03 and p < 0.001, respectively).<br />Conclusion: Lymphadenectomy during IDS does not improve survival and increases post-operative complications.<br />Competing Interests: Declaration of competing interest None.<br /> (Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)
- Subjects :
- Aged
Antineoplastic Agents therapeutic use
Carcinoma, Ovarian Epithelial pathology
Disease-Free Survival
Female
Humans
Middle Aged
Neoadjuvant Therapy
Neoplasms, Cystic, Mucinous, and Serous pathology
Ovarian Neoplasms pathology
Retrospective Studies
Risk Assessment
Survival Rate
Carcinoma, Ovarian Epithelial surgery
Cytoreduction Surgical Procedures methods
Lymph Node Excision methods
Neoplasms, Cystic, Mucinous, and Serous surgery
Ovarian Neoplasms surgery
Postoperative Complications epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1532-2157
- Volume :
- 48
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 34753619
- Full Text :
- https://doi.org/10.1016/j.ejso.2021.10.027